Molecules of the Month – Where Are They Now? …and Other Short Stories

Two past Molecules of the Month inductees had significant updates recently, showing they’re still moving forward:


This September ‘22 Molecule of the Month is an IV calcium-sensing receptor (CaSR) agonist first identified in flavor studies of peptides. It is already approved in Japan for secondary hyperparathyroidism (SHPT), and now Pathalys Pharma has raised $150M to advance its development outside of Japan and Asia through additional Ph. III trials.


This oral, once-daily CETP inhibitor and August ‘22 Molecule of the Month recently met its primary endpoint of LDL-C lowering in a Ph. II study (NCT05266586) in combination with ezetimibe as an adjunct to high-intensity statin therapy. The combination had a safety profile comparable to placebo, and NewAmsterdam is advancing the program to Ph. III. CETP inhibitors were intensely studied over a decade ago and this is a continued sign of a second life for this Amgen molecule in high-risk cardiovascular disease patients, a more narrow indication than originally intended.

In our full update of small molecules in the news we also cover recent:

  • (B/M)illion-Dollar Molecules: recent M&A’s, IPOs, and other fundraising
  • Molecules in Motion: clinical trial updates and FDA filings
  • Where Are They Now? updates on past Drug Hunter Molecules of the Month
  • Potential Upcoming Approvals: recent NDA filings and upcoming PDUFA dates

Read about all 14 molecules in the full Premium article here.

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

This field is for validation purposes and should be left unchanged.